Investors Purchase Large Volume of Microbot Medical Call Options (NASDAQ:MBOT)

Microbot Medical Inc. (NASDAQ:MBOT) was the target of unusually large options trading activity on Monday. Traders purchased 2,704 call options on the stock. This is an increase of 122% compared to the typical daily volume of 1,216 call options.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Microbot Medical in a research note on Thursday, April 10th.

Microbot Medical Stock Performance

Microbot Medical stock opened at $2.49 on Tuesday. Microbot Medical has a fifty-two week low of $0.82 and a fifty-two week high of $3.38. The firm has a 50 day moving average price of $2.38 and a 200 day moving average price of $1.83. The company has a market capitalization of $90.58 million, a PE ratio of -3.11 and a beta of 1.14.

Microbot Medical (NASDAQ:MBOT) last issued its earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.07. As a group, equities research analysts forecast that Microbot Medical will post -0.71 earnings per share for the current year.

Institutional Investors Weigh In On Microbot Medical

A number of hedge funds have recently added to or reduced their stakes in MBOT. Geode Capital Management LLC increased its stake in shares of Microbot Medical by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 10,442 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Microbot Medical during the 1st quarter valued at $42,000. Goldman Sachs Group Inc. acquired a new position in shares of Microbot Medical during the 1st quarter valued at $57,000. Finally, Renaissance Technologies LLC acquired a new position in Microbot Medical in the 4th quarter worth $118,000. Institutional investors and hedge funds own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.